Recherche
-
HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates
(PLoS ONE. vol. 13, n° 11, pp. e0207794, 2018-11-30)Article de revueLibre accès -
Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination
(International Journal of Infectious Diseases. vol. 74, pp. 83-96, 2018-09)Article de revueLibre accès -
PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study
(The Lancet Infectious Diseases. vol. 20, n° 5, pp. 585-597, 2020)Article de revue -
Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect
(Journal of Immunological Methods. vol. 477, pp. 112711, 2020)Article de revue -
Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions
(The Lancet HIV. vol. 6, n° 5, pp. e334-e340, 2019-05)Article de revueLibre accès -
Influence of the Antiretroviral Regimen on the Early Changes in Plasma HIV RNA and Immune Activation at Initiation of Antiretroviral Therapy in Naïve HIV-1–Infected Patients
(Journal of Acquired Immune Deficiency Syndromes. vol. Publish Ahead of Print, 2020-12-17)Article de revue -
T-cell and Transcriptomic Responses to Prime-boost Strategies of 3 HIV Vaccines (MVA HIV-B
(AIDS Research and Human Retroviruses. pp. 16-16, 2018-10)Article de revue -
A Phase Ia/B Study To Assess The Safety And Immunogenicity Of Placental Malaria Vaccine Candidate: Preliminary Results Of The Primalvac Trial
(American Journal of Tropical Medicine and Hygiene. vol. 99, n° 4, pp. 469-469, 2018)Article de revue -
Durable natural killer cell responses after heterologous two-dose Ebola vaccination
(NPJ vaccines. vol. 6, n° 1, pp. 19, 2021-01-29)Article de revueLibre accès -
T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial
(Journal of Immunology. vol. 208, n° 12, pp. 2663-2674, 2022-06-15)Article de revue